Subscribe for perks & to support LI

Your Interests & Preferences: Personalise your reading

Which best describes your role and/or interests?

I work in a law firm
I work for a company / in-house
I'm a litigator at the bar
I'm a law student
Aspiring law student
Save setting
Or click here to show more preferences...

I am interested in the following types of stories (uncheck to hide from frontpage)

Firms / In-House
Legal Education

Always show me: (overrides the above)

Exclusives & Editor's Picks

Website Look & Feel

Light Text on Dark Background

Save preferences

Note: Your preferences will be saved in your browser. You can always change your settings by clicking the Your Preferences button at the top of every page.

Reset preferences to defaults?

Veritas acts on $39m Recipharm acquisition of remaining 26% stake of Nitin Lifesciences with Khaitan

Recipharm acquired the remaining 26% stake of NLL from its existing shareholders in 2 stages. The first stage for a cash consideration, has been completed on 2 January 2018. The second stage for the acquisition of the balance of the share capital of NLL is proposed to be completed during the first half of 2018, for which the consideration is proposed to be paid in newly issued Recipharm shares (subject to receipt of regulatory approvals). Post this, Recipharm will own 100% of NLL, according to the company.

Veritas Legal advised Recipharm AB led by a team of partner Nandish Vyas, senior associate Natasha Sethna, and associate Tejasvi Saxena.

Recipharm also relied on PricewaterhouseCoopers.

Khaitan & Co acted for selling family and Nitin LifeSciences Limited, led by partner Kalpana Unadkat, principal associate Pranay Bagdi and associate Bidya Mohanty.


Deal value: Rs 2.8 crore (approx)

Latest comments